$6.75
Price
$340M
Market Cap
9.1
P/E Ratio
12.3
Forward P/E
$0.74
EPS (TTM)
—
Dividend Yield
$94M
Cash
$74M
Total Debt
50M
Shares Out
$2.58
$7.29
52-Week Range
Institutional Ownership of PUMA BIOTECHNOLOGY INC
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
|
Causeway Capital Management|Sarah Ketterer
|
13.3K | $79195 | $3.07 | +107.82% |
Trading Activity for PUMA BIOTECHNOLOGY INC
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| 2025-Q4 | |||||
| SELL | -5.6% | 13.3K | $79195 | $5.23 | |
| 2025-Q1 | |||||
| BUY | NEW | 14.1K | $41721 | $3.07 | |
| 2018-Q4 | |||||
| SELL | EXIT | — | — | $23.57 | |
| 2018-Q3 | |||||
| BUY | NEW | 151.7K | $7M | $47.50 | |
Insider Trading for PUMA BIOTECHNOLOGY INC
6 Months Insider Sentiment
Buy $0
Sell $419K
0
Buys
7
Sells
-419K
Net
0
Grants
Largest
$106K
Auerbach
$99K
Auerbach
$97K
Miller
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 07, 2026 | Douglas M Hunt | The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer. | SELL | 5.0K | $5.88 | $29K |
| Jan 07, 2026 | Alan H Auerbach | President and CEO | SELL | 18.0K | $5.88 | $106K |
| Jan 07, 2026 | Maximo F Nougues | Chief Financial Officer | SELL | 6.4K | $5.88 | $38K |
| Jan 06, 2026 | Alan H Auerbach | President and CEO | SELL | 16.9K | $5.84 | $99K |
| Jan 06, 2026 | Maximo F Nougues | Chief Financial Officer | SELL | 4.5K | $5.84 | $27K |
| Jan 06, 2026 | Douglas M Hunt | The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer. | SELL | 4.0K | $5.84 | $23K |
| Nov 11, 2025 | Michael Patrick Miller | Director | SELL | 20.0K | $4.86 | $97K |